Novavax Raises FY26 Revenue Outlook by More Than 50%
Novavax raised its full-year 2026 adjusted revenue outlook by more than 50% at the upper end, supported by growing revenue opportunities from vaccine licensing partnerships.
Novavax (NVAX) was on investors’ radar on Thursday, after the company raised its full-year 2026 revenue outlook by more than 50% at the upper end, supported by growing revenue opportunities from vaccine licensing partnerships.Novavax raised its full-year 2026 adjusted revenue outlook to $385 millio…